Key Takeaways
- In China, assisted reproductive technologies are specifically approved. Check the institution and the exact authorised technique; approval for one form of insemination does not prove approval for IVF, ICSI, donor sperm, or PGT.
- Confirm eligibility and documents in writing before paying or booking travel. Published Chinese rules and ethics principles prohibit surrogacy, gamete and embryo trading, non-medical sex selection, and access outside specified ethical and legal conditions.
- A clinic’s “success rate” is meaningless without age, egg source, diagnosis, cycle stage, denominator, time period, cancellations, and whether the endpoint is pregnancy or live birth.
- The laboratory is part of the treatment. Ask about witnessing, identity control, incubators, cryostorage, alarms, backup power, adverse-event review, and custody of eggs, sperm, and embryos.
- Plan more than the transfer: stimulation monitoring, unexpected responses, retrieval, complications, freezing, consent changes, pregnancy confirmation, early obstetric care, and transfer of records home.
Content
Two clinics can both advertise “60% success” while describing completely different events. One may mean a positive pregnancy test per embryo transfer in selected younger patients; another may mean live birth per egg collection across all patients. Until the denominator is visible, the percentage is decoration.
For an international patient considering treatment in China, the selection order should be: eligibility → authorised technology → patient-specific clinical plan → laboratory chain → comparable outcomes → full-cycle logistics.
Confirm eligibility before discussing a protocol
Send the centre the patients’ nationalities, ages, marital/legal status, identity-document names, diagnosis, requested use of own or donor gametes, relevant genetic issue, and whether fertility preservation rather than immediate conception is sought. Ask for a written list of documents and an eligibility decision from the authorised reproductive-medicine service—not a travel coordinator’s assumption.
China’s published assisted-reproduction rules require treatment in an approved medical institution, informed consent, and compliance with ethical and legal requirements. They prohibit buying or selling gametes, zygotes, or embryos and prohibit surrogacy [1]. The published ethics principles also restrict access outside the specified couple-based legal framework and prohibit non-medical sex selection [2]. Because facts and local implementation can differ, obtain a current written check for the exact patient and pathway before making non-refundable arrangements.
If a proposal includes commercial surrogacy, buying eggs or sperm, choosing sex without a medical indication, or transferring material through an unapproved intermediary, stop. A polished international website does not convert a prohibited or unapproved service into lawful care.
Verify the exact technology, not only the clinic name
The National Health Commission publishes a current list of institutions approved to provide specific assisted reproductive technologies and to operate human sperm banks [3]. Match the legal Chinese institution name, campus, and approved items. Common categories are not interchangeable:
Clinical need · Possible pathway · What must be verified
timing or ovulatory problem · assessment, ovulation management, timed intercourse · diagnosis, monitoring and escalation threshold
suitable couple using partner sperm · husband insemination (AIH/IUI) · specific approval and semen/ovulation criteria
use of donor sperm · donor insemination or relevant IVF route · approved donor-sperm service and authorised sperm-bank chain
tubal, severe male-factor or other indicated infertility · IVF–embryo transfer · IVF approval, clinical and embryology teams
defined fertilisation problem · ICSI · indication, laboratory competence and outcome reporting
eligible serious genetic condition · PGT · specific PGT authorisation, genetics, laboratory validation and ethics review
fertility preservation before gonadotoxic treatment · time-critical preservation pathway · eligibility, oncology coordination, storage and future-use conditions
A centre approved for AIH is not thereby approved for IVF. A centre approved for routine IVF/ICSI is not thereby approved for PGT. Chinese approval requirements treat PGT as an additional capability with its own experience threshold [4].
Begin with both partners and the reproductive goal
Write down whether the goal is diagnosis, natural-conception optimisation, IUI, IVF, preservation, avoiding transmission of a defined condition, or another lawful pathway. Then build a dated evidence packet for both partners where applicable:
- menstrual and pregnancy history, prior births and losses, pelvic surgery, infection, pain, and treatment response;
- fertility-treatment cycle sheets—not only discharge summaries—including drug doses, follicle counts, hormone results, retrieval, fertilisation, embryo development, transfer and storage;
- ovarian reserve and endocrine tests with date, units and laboratory range;
- pelvic ultrasound images/reports and tubal/uterine assessment where indicated;
- at least one properly collected semen analysis and relevant male history;
- genetic reports with the original laboratory method and variant classification;
- current medicines/supplements, allergies, BMI, smoking/alcohol, infectious-disease testing, chronic disease and anaesthetic history;
- identity and relationship documents requested by the centre.
The WHO’s 2025 infertility guideline frames care as a progression from diagnosis and simpler management to more complex treatment according to evidence and individual circumstances [5]. Male assessment should not be reduced to a screenshot of one semen value; the WHO laboratory manual standardises collection, processing, examination and quality procedures so results can be interpreted in context [6].
Ask for one written patient-specific decision tree
The preliminary response should state:
- working diagnosis and unresolved questions;
- whether the centre considers the patient eligible and what documents remain;
- the proposed first-line path and why;
- alternatives, including no treatment or treatment at home;
- tests that must be repeated and how they would change the plan;
- medication and monitoring outline;
- thresholds for cancelling, changing trigger, freezing all embryos, converting, or stopping;
- likely number and timing of visits;
- major risks and the service that manages them;
- who makes decisions when the named consultant is unavailable.
Be cautious if age or a low ovarian-reserve marker is presented as a guaranteed number of eggs, embryos, or babies. Prognostic estimates should show their population and uncertainty. A responsible centre can explain a poor prognosis without either selling certainty or withholding options.
Inspect the clinical–laboratory chain
An IVF programme is a paired system: the clinical team manages the patient; the laboratory manages sperm, oocytes, embryos, culture conditions and storage. Ask the centre to explain the chain without revealing another patient’s confidential data:
- how identity is checked at collection, retrieval, insemination/ICSI, culture, biopsy, freezing, thawing and transfer;
- whether critical steps require two-person or electronic witnessing;
- who directs the embryology laboratory and how competency is assessed;
- how temperature, gases, incubators and culture conditions are monitored;
- how tanks are labelled, mapped, alarmed and audited;
- backup electricity, emergency gas/storage capacity and escalation after an alarm;
- contamination, equipment-failure, misidentification and near-miss reporting;
- custody rules, storage fees, renewal, consent withdrawal, prolonged loss of contact and material disposition;
- how records and material would be handled if the service moved, suspended work or closed.
Chinese management provisions require complete, accurate records of cases and the destination and outcome of gametes and embryos, with permanent preservation of specified donor-treatment records and legal documents [7]. “We have never had a problem” is not a quality system; ask how problems are prevented, detected, disclosed and learned from.
Recalculate every success claim
Request data for the same age band, egg source, diagnosis or prognosis group, and proposed treatment. Put these fields beside every percentage:
- endpoint: biochemical pregnancy, ultrasound clinical pregnancy, ongoing pregnancy, or live birth;
- denominator: cycle started, stimulation, egg retrieval, transfer, or embryo transferred;
- fresh or frozen; own or donor eggs;
- single transfer or multiple embryos transferred;
- reporting period and number of patients/cycles;
- cancellations and cycles with no transferable embryo;
- cumulative live birth from one egg collection, including subsequent frozen transfers;
- miscarriage, ectopic pregnancy, multiple pregnancy/birth, ovarian hyperstimulation, retrieval complication, and loss to follow-up.
Fertility regulators warn that small differences can reflect patient mix or chance and that clinic rates cannot predict an individual patient’s outcome [8]. The denominator most useful to the patient may be cumulative live birth per started cycle or retrieval, not a high pregnancy rate per selected transfer. Also ask whether the clinic transfers one embryo when clinically appropriate and reports multiple birth; a high twin rate is not a hidden bonus.
Separate core treatment from optional add-ons
Ask the clinician to label each intervention as:
- standard and indicated for this diagnosis;
- optional with evidence for this patient subgroup;
- uncertain or experimental;
- part of a registered research protocol.
For assisted hatching, time-lapse selection, immune tests or treatments, endometrial tests, platelet-rich plasma, “mitochondrial” claims, routine freeze-all, sperm-selection methods, or other extras, request the proposed mechanism, patient-specific indication, live-birth evidence, safety, alternative, price, and whether care is available without it. The HFEA notes that many add-ons lack evidence of improving outcomes for most patients and that standard treatment may be effective without them [9].
PGT is not a generic embryo “quality upgrade.” Ask which condition or chromosome question is being tested, whether genetic counselling occurred, the assay and validation, possible no-result or mosaic findings, biopsy/freezing implications, confirmatory prenatal testing, and what decisions follow each result. Non-medical sex selection is not an acceptable substitute for an indication.
Make consent a continuing process
Consent should cover stimulation, anaesthesia/retrieval, fertilisation method, number of embryos transferred, freezing and thawing, storage period and fees, PGT if applicable, research, data sharing, future contact, material disposition, and what happens if one party withdraws consent or circumstances change.
Arrange qualified interpretation for clinical and consent discussions. The signed Chinese form, any translated explanation, and the final agreed decisions should match. Do not sign blank choices for embryo disposition or permit a coordinator to summarise an ethical decision that the responsible clinician has not discussed.
Stress-test the schedule and emergency plan
Fertility cycles move with biology, not airline tickets. Ask which monitoring can occur at home, which assays and ultrasound measurements the Chinese team accepts, how quickly results must arrive, and who adjusts doses across time zones. Keep flexible arrival and departure dates.
Confirm the plan for poor or excessive ovarian response, medication error, severe pain, bleeding, fever, ovarian torsion, ovarian hyperstimulation, anaesthetic complication, or an unexpected pregnancy problem. Identify the emergency department and obstetric/gynaecological support at the exact campus, plus an after-hours contact that is more than a sales account.
Price one complete decision cycle
Request separate estimates for records review, consultation, repeat testing, medicines, monitoring, retrieval and anaesthesia, laboratory fertilisation, culture, ICSI if conditional, biopsy and genetic testing, freezing, storage, transfer, pregnancy testing, early ultrasound, interpretation, and records. Add likely costs if the cycle is cancelled, no oocyte is retrieved, no embryo is suitable, stimulation is prolonged, all embryos are frozen, a second transfer is needed, or a complication occurs.
Clarify which payments are refundable, how unused medicines are handled, annual storage renewal, currency/transfer charges, and whether invoices identify the legal medical institution. A low “IVF package” can exclude medicines, ICSI, freezing, storage or frozen transfer.
Design the handoff around the next biological event
Before leaving, obtain the stimulation and monitoring chart, retrieval and anaesthetic note, semen preparation, fertilisation method, embryo-development and disposition record, transfer note, storage inventory and consent, medicines, complications, pregnancy-test date, early-ultrasound plan, warning signs and named contacts.
If pregnant, arrange obstetric care at home for location and viability assessment, multiple pregnancy, medicines, and relevant genetic/prenatal follow-up. If not pregnant or if no embryo is available, schedule a review that addresses what was learned and whether another attempt is medically, emotionally and financially reasonable. The centre has not completed its work when an embryo is transferred; it has completed a safe cycle when the record, stored material, result and next responsibility are all accounted for.
Medical disclaimer: This guide provides general selection and planning information and does not determine legal eligibility, diagnose infertility, recommend a fertility treatment, or rank Chinese centres. Regulations, documents and clinical eligibility must be confirmed for the specific patient with an authorised institution.
Related Hospitals
List a fertility centre only after matching its legal Chinese institution name and exact authorised technology in the current official list, then verifying the responsible team, laboratory chain, emergency support, outcome definitions, costs, and follow-up.
Related Treatments
Link only a lawful, authorised, patient-indicated pathway such as evaluation, ovulation management, AIH, donor insemination, IVF, ICSI, eligible PGT, preservation, or counselling; do not present add-ons as routine.
Related Guides
- IVF in China: A Cycle-by-cycle Planning Guide
- Understanding Fertility-clinic Success Rates
- PGT in China: Indications, Limits, and Consent
- Fertility Preservation before Cancer Treatment
- Translating and Transferring Embryology Records
FAQ
Can any Chinese hospital with a fertility clinic perform IVF?
No. Check the National Health Commission’s current approved-institution list and the exact technologies authorised for that institution. Approval for insemination alone does not establish approval for IVF, ICSI, donor sperm, or PGT.
What is the fairest way to compare success rates?
Use the same age band, egg source, prognosis, endpoint, and denominator. Ask for live birth and cumulative live birth per started cycle or retrieval, plus cancellations, multiple birth, complications and follow-up—not only pregnancy per transfer.
Is ICSI better than standard IVF for everyone?
No. It is a fertilisation technique used for defined situations. Ask for the indication, alternatives, laboratory data and whether it changes live-birth prospects in this patient rather than paying for it automatically.
Should every IVF cycle include PGT or other add-ons?
No. Each test or add-on needs a patient-specific indication, evidence for a meaningful outcome such as live birth, safety information and a clear decision it will change. Some services are uncertain or experimental.
What records should be taken home after a cycle?
Keep monitoring and medication charts, retrieval and fertilisation data, embryo-development and disposition records, transfer note, cryostorage inventory and consent, complications, results, invoices, and the next pregnancy or review plan.
Sources
- National Health Commission: Measures for the Administration of Human Assisted Reproductive Technology
- National Health Commission: Technical Standards and Ethical Principles for Assisted Reproduction and Human Sperm Banks
- National Health Commission: Approved Assisted-reproduction Institutions and Human Sperm Banks
- National Health Commission: Supplementary Approval Rules for Assisted Reproduction and Human Sperm Banks
- World Health Organization: Guideline for the Prevention, Diagnosis and Treatment of Infertility, 2025
- World Health Organization: Laboratory Manual for the Examination and Processing of Human Semen, 6th ed.
- National Health Commission: Provisions Strengthening Management of Assisted-reproduction Institutions and Personnel
- UK Human Fertilisation and Embryology Authority: Choosing a Fertility Clinic and Reading Success Rates
- UK Human Fertilisation and Embryology Authority: Treatment Add-ons with Limited Evidence
Hero Image Prompt
Generated with the built-in image tool for this article: an unbranded reproductive-medicine consultation connecting a couple’s anonymised identity and treatment checkpoints with an embryology laboratory, witnessing process, incubator, and controlled storage. It does not show a real embryo, record, institution, treatment outcome, or endorsement.